
Chemomab Therapeutics Investor Relations Material
Latest events

Study Result
Chemomab Therapeutics

Q1 2025
15 May, 2025

Q4 2024
3 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Chemomab Therapeutics Ltd
Access all reports
Chemomab Therapeutics Ltd is an Israel-based clinical-stage biotechnology company focused on the development of therapies for fibrotic and inflammatory diseases. The company’s lead drug candidate is based on targeting CCL24, a chemokine involved in fibrosis and inflammation. Chemomab's pipeline includes treatments for conditions such as primary sclerosing cholangitis (PSC) and systemic sclerosis. The company conducts preclinical and clinical studies and collaborates with research institutions to advance its drug development efforts. Chemomab Therapeutics Ltd is headquartered in Tel Aviv, Israel, and its shares are listed on the NASDAQ.
Key slides for Chemomab Therapeutics Ltd


Study Result
Chemomab Therapeutics Ltd


Study Result
Chemomab Therapeutics Ltd
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
CCMB
Country
🇺🇸 United States